Anti-VEGF Market Trends
The Anti-VEGF Market is defined by several transformative trends that are reshaping the industry's future. One of the most significant trends is the rapid influx of biosimilars. With the patents for key blockbuster drugs like Lucentis and Eylea expiring, several companies are introducing biosimilar versions that offer a more cost-effective alternative. This trend is expected to increase market competition and make these life-changing treatments more accessible to a broader patient population, particularly in developing economies with limited healthcare budgets.
Another major trend is the development of longer-acting therapies. The current standard of care often involves frequent intravitreal injections, which can be a significant burden for patients and healthcare providers. Companies are actively developing extended-release formulations, such as Eylea HD and port delivery systems, to reduce the injection frequency from monthly to quarterly or even less. This not only improves patient convenience and compliance but also has the potential to improve long-term visual outcomes. The market is also seeing a trend towards bispecific antibodies, which target multiple pathways to achieve a more potent therapeutic effect.